ArticleCancer medicine2021
Prognostic factors and survival prediction in HER2-positive breast cancer with bone metastases: A retrospective cohort study.
Article in Cancer medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- The prognosis of breast cancer patients with bone metastasis could be potentially estimated based on blood routine test and biochemical examination at admission.Annals of medicine · 2023Trial
- Prognostic model for pulmonary metastasis in patients with HER2-positive breast cancer: a population-based study.Breast cancer (Tokyo, Japan) · 2026Article
- Development and validation of a nomogram for prognosis of bone metastatic disease in patients with esophageal squamous cell carcinoma: A retrospective study in the SEER database and China cohort.Journal of bone oncology · 2025Article
- Factors Associated With Short- and Long-Term Survival in Metastatic HER2-Positive Breast Cancer.Clinical breast cancer · 2025Article
- Development and validation of a nomogram for predicting bone metastasis in breast cancer: a retrospective study.Frontiers in surgery · 2025Article
- Development of prognostic models for HER2-positive metastatic breast cancer in females: a retrospective population-based study.BMC women's health · 2024Article
- A network dynamic nomogram for predicting overall survival and cancer-specific survival in patients with breast cancer liver metastases: an analysis based on the SEER database.Discover oncology · 2024Article
- Prognostic nomograms for young breast cancer: A retrospective study based on the SEER and METABRIC databases.Cancer innovation · 2024Review
- Development and Validation of a Prognostic Nomogram Model for HER2-Positive Male Breast Cancer Patients.Asian Pacific journal of cancer prevention : APJCP · 2024Article
- Risk factors, prognostic factors, and nomograms for synchronous brain metastases of solid tumors: a population-based study.Neurosurgical review · 2024Article
- Tailoring Potential Natural Compounds for the Treatment of Luminal Breast Cancer.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Predicting survival of patients with bone metastasis of unknown origin.Frontiers in endocrinology · 2023Article
- Recent Trends in Synchronous Brain Metastasis Incidence and Mortality in the United States: Ten-Year Multicenter Experience.Current oncology (Toronto, Ont.) · 2022Article
- Predicting Response to Radiotherapy in Breast Cancer-Induced Bone Pain: Relationship Between Pain and Serum Cytokine Expression Levels After Radiotherapy.Journal of pain research · 2022Article
- Development and Validation of Prognostic Nomogram for Elderly Breast Cancer: A Large-Cohort Retrospective Study.International journal of general medicine · 2022Article
- Prognostic factors and survival prediction in HER2-positive breast cancer with bone metastases: A retrospective cohort study.Cancer medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBone is the most common metastatic site of breast cancer. The developmental pattern of bone metastasis differs in different molecular subtypes. The prognostic factors of HER2-positive breast cancer with bone metastases require further investigation. The goal of this retrospective study was to identify the clinical features and prognostic factors for HER2-positive patients with bone metastases.
methodsA total of 34,084 HER2-positive breast cancer cases and 1204 cases of bone metastases from the Surveillance, Epidemiology, and End Results (SEER) database from 2010 to 2015 were analyzed to identify clinical characteristics and prognostic factors. A nomogram was constructed based on the Cox proportional hazards regression model. The C-index, calibration curve, and receiver operating characteristic (ROC) were utilized for model validation.
resultsIn the HER2-positive breast cancer total population (34,084 cases), 6.2% developed metastatic diseases. Bone metastases accounted for 3.5% of the entire cohort and 56.7% of all metastatic cases. Univariate and multivariate Cox regression analyses identified seven prognostic factors for predicting cancer-specific survival (CSS) for HER2-positive breast cancer patients with bone metastases, including age, brain metastases, liver metastases, lung metastases, PR status, surgery, and chemotherapy. The C-index of the nomogram was 0.74 vs. 0.78 (for 3-year CSS) and 0.77 vs. 0.81 (for 5-year CSS) in the model and validation cohorts, respectively. The AUCs were 0.74 vs. 0.78 (for 3-year CSS) and 0.77 vs. 0.81 (for 5-year CSS) in the model and validation cohorts, respectively. The calibration curves indicated favorable agreement between the actual observations and the predictions.
conclusionOur study provided population-based clinical features and prognostic factors for HER2-positive breast cancer patients with bone metastases and we constructed a prognostic nomogram with reliable accuracy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.